Coherus BioSciences (CHRS) Reports Q2 Loss of $1.56
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.46 --0%
Revenue Growth %: +91.8%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +91.8%
Financial Fact:
Gross profit: 261.73M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($1.56), versus ($5.90) reported last year. Revenue for the quarter came in at $6.87 million, versus $4.46 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- BTIG Starts Take-Two Interactive (TTWO) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
